Do you support this bill?

Assembly Bill A6927A

2025-2026 Legislative Session

Relates to prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy

download bill text pdf

Sponsored By

Current Bill Status - In Assembly Committee

Please enter your contact information

Home address is used to determine the senate district in which you reside. Your support or opposition to this bill is then shared immediately with the senator who represents you.

Optional services from the NY State Senate:

Create an account. An account allows you to officially support or oppose key legislation, sign petitions with a single click, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.

Include a custom message for your Senator? (Optional)

Enter a message to your senator. Many New Yorkers use this to share the reasoning behind their support or opposition to the bill. Others might share a personal anecdote about how the bill would affect them or people they care about.

Actions

Bill Amendments

co-Sponsors

2025-A6927 - Details

See Senate Version of this Bill:
S10466
Current Committee:
Assembly Higher Education
Law Section:
Education Law
Laws Affected:
Amd §§6807 & 6810, Ed L; amd §280-d, Pub Health L

2025-A6927 - Summary

Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

2025-A6927 - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                   6927
 
                        2025-2026 Regular Sessions
 
                           I N  A S S E M B L Y
 
                              March 18, 2025
                                ___________
 
 Introduced by M. of A. SIMONE -- read once and referred to the Committee
   on Higher Education
 
 AN ACT to amend the education law and the public health law, in relation
   to prescription labels for mifepristone, misoprostol, gonadotropin-re-
   leasing  hormone  agonists,  pubertal suppressants, anabolic steroids,
   alpha reductase inhibitors, progestins, or drug  classes  for  hormone
   replacement therapy for treatment of gender dysphoria
 
   THE  PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section 1. Paragraph b-1 of subdivision  1  of  section  6807  of  the
 education  law, as added by chapter 7 of the laws of 2025, is amended to
 read as follows:
   b-1. Notwithstanding paragraph b of  this  section,  the  prescription
 label  for  mifepristone,  misoprostol, [and their generic alternatives]
 GONADOTROPIN-RELEASING HORMONE AGONISTS, PUBERTAL SUPPRESSANTS, ANABOLIC
 STEROIDS, ALPHA REDUCTASE INHIBITORS, PROGESTINS, OR  DRUG  CLASSES  FOR
 HORMONE  REPLACEMENT  THERAPY  FOR  TREATMENT  OF  GENDER DYSPHORIA, may
 include the name OR ADDRESS  of  the  dispensing  health  care  practice
 instead of the name of the dispenser.
   § 2. Subdivision 1-a of section 6810 of the education law, as added by
 chapter 7 of the laws of 2025, is amended to read as follows:
   1-a.   Notwithstanding   subdivision  one  of  this  section,  at  the
 prescriber's request, the prescription label for mifepristone, misopros-
 tol, [and their  generic  alternatives]  GONADOTROPIN-RELEASING  HORMONE
 AGONISTS,  PUBERTAL  SUPPRESSANTS,  ANABOLIC  STEROIDS,  ALPHA REDUCTASE
 INHIBITORS, PROGESTINS, OR DRUG CLASSES FOR HORMONE REPLACEMENT  THERAPY
 FOR TREATMENT OF GENDER DYSPHORIA, may include the name of the prescrib-
 ing health care practice instead of the name of the prescriber.
   § 3. The public health law is amended by adding a new section 280-d to
 read as follows:
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD10852-01-5
 A. 6927                             2

co-Sponsors

2025-A6927A (ACTIVE) - Details

See Senate Version of this Bill:
S10466
Current Committee:
Assembly Higher Education
Law Section:
Education Law
Laws Affected:
Amd §§6807 & 6810, Ed L; amd §280-d, Pub Health L

2025-A6927A (ACTIVE) - Summary

Provides that prescription labels for gonadotropin-releasing hormone agonists, pubertal suppressants, anabolic steroids, alpha reductase inhibitors, progestins, or drug classes for hormone replacement therapy maybe include the name of the dispensing practice instead of the prescriber; provides for notice to patients.

2025-A6927A (ACTIVE) - Bill Text download pdf 

                             
                     S T A T E   O F   N E W   Y O R K
 ________________________________________________________________________
 
                                  6927--A
 
                        2025-2026 Regular Sessions
 
                           I N  A S S E M B L Y
 
                              March 18, 2025
                                ___________
 
 Introduced  by  M.  of A. SIMONE, TAPIA, GONZALEZ-ROJAS, REYES, SHIMSKY,
   GLICK, SCHIAVONI, LUNSFORD, ROMERO, MEEKS, BRONSON, SEAWRIGHT, HEVESI,
   SIMON, ROSENTHAL, RAGA, LEE, WRIGHT, LEVENBERG, KELLES  --  read  once
   and  referred  to  the Committee on Higher Education -- recommitted to
   the Committee on Higher Education in accordance with Assembly Rule  3,
   sec.  2  --  committee  discharged, bill amended, ordered reprinted as
   amended and recommitted to said committee
 
 AN ACT to amend the education law and the public health law, in relation
   to prescription labels for  gonadotropin-releasing  hormone  agonists,
   pubertal  suppressants, anabolic steroids, alpha reductase inhibitors,
   progestins, or drug classes for hormone replacement therapy for treat-
   ment of gender dysphoria
 
   THE PEOPLE OF THE STATE OF NEW YORK, REPRESENTED IN SENATE AND  ASSEM-
 BLY, DO ENACT AS FOLLOWS:
 
   Section  1.  Paragraph  b-1  of  subdivision  1 of section 6807 of the
 education law, as amended by chapter 108 of the laws of 2025, is amended
 to read as follows:
   b-1. Notwithstanding paragraph b of this  [section]  SUBDIVISION,  the
 prescription  label for mifepristone [or], misoprostol, GONADOTROPIN-RE-
 LEASING HORMONE  AGONISTS,  PUBERTAL  SUPPRESSANTS,  ANABOLIC  STEROIDS,
 ALPHA  REDUCTASE  INHIBITORS,  PROGESTINS,  OR  DRUG CLASSES FOR HORMONE
 REPLACEMENT THERAPY FOR TREATMENT OF GENDER DYSPHORIA, may  include  the
 name  or  address  of the dispensing health care practice instead of the
 name of the dispenser.
   § 2. Subdivision 1-a of section 6810 of the education law, as  amended
 by chapter 108 of the laws of 2025, is amended to read as follows:
   1-a.   Notwithstanding   subdivision  one  of  this  section,  at  the
 prescriber's request, the  prescription  label  for  mifepristone  [or],
 misoprostol,  GONADOTROPIN-RELEASING HORMONE AGONISTS, PUBERTAL SUPPRES-
 SANTS, ANABOLIC STEROIDS, ALPHA  REDUCTASE  INHIBITORS,  PROGESTINS,  OR
 DRUG  CLASSES  FOR  HORMONE  REPLACEMENT THERAPY FOR TREATMENT OF GENDER
 
  EXPLANATION--Matter in ITALICS (underscored) is new; matter in brackets
                       [ ] is old law to be omitted.
                                                            LBD10852-03-6

Comments

Open Legislation is a forum for New York State legislation. All comments are subject to review and community moderation is encouraged.

Comments deemed off-topic, commercial, campaign-related, self-promotional; or that contain profanity, hate or toxic speech; or that link to sites outside of the nysenate.gov domain are not permitted, and will not be published. Attempts to intimidate and silence contributors or deliberately deceive the public, including excessive or extraneous posting/posts, or coordinated activity, are prohibited and may result in the temporary or permanent banning of the user. Comment moderation is generally performed Monday through Friday. By contributing or voting you agree to the Terms of Participation and verify you are over 13.

Create an account. An account allows you to sign petitions with a single click, officially support or oppose key legislation, and follow issues, committees, and bills that matter to you. When you create an account, you agree to this platform's terms of participation.